Low-dose CT screening linked to reduction in lung cancer mortalitySeptember 13, 2021
Low-dose CT (LDCT) lung cancer screening is associated with a 16 percent relative reduction in related mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team at the IASLC 2021 World Conference on Lung Cancer. The research will be published in the Lancet Regional Health-Europe.
The UKLS is a randomized controlled trial, comparing LDCT screening with usual care in a high-risk population selected using the LLPv2 risk model, and having a unique Wald single LDCT screening design, in a high-risk population.
Risks for the UKLS were calculated using LLPv2, which is a modified version of the published LLP model, which incorporates age, smoking duration, family history of lung cancer, history of previous malignancies and exposure to asbestosis and other potential respiratory risk factors (bronchitis, emphysema, tuberculosis and COPD) in addition to pneumonia, and treats cigar and pipe smoking as conferring an identical risk to cigarette smoking.
Led by Prof. John Field, of The University of Liverpool, Liverpool, United Kingdom, researchers randomly allocated 4055 participants, October 2011 to February 2013, with either a single invitation to LDCT screening or no screening (usual care). Data were collected on lung cancer cases and deaths to 29-February-2020 through linkage to national registries. The primary outcome was mortality due to lung cancer.
Prof. Field’s team analysed UKLS participants in the intervention group and in the usual-care group and followed them for 7.4 years. It has to be noted that the relative benefit in terms of lung cancer mortality was seen most strongly in the three to six years after randomization.
LDCT screening was associated with a 16% relative reduction in lung cancer mortality, when compared against a non-LDCT control group.